Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 91.88M shares outstanding
USContext Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors.
Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Andy Pasternak
Chairman of the Board
Jennifer Evans Stacey, Esq.
Director
Karen Smith, MD, PhD, MBA, LLM
Director
Linda West
Director
Employees
15
Country
US
Sector
Healthcare
Website
contexttherapeutics.com
Loading congressional disclosures…
based on 91.88M shares outstanding
US30d Avg
1.09M
60d Avg
1.52M
90d Avg
1.58M
